Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica
Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica
复制标题
DOI：
10.1016/j.vetmic.2012.05.006
复制
发表时间：
2012-11-09
影响因子：
3.3
通讯作者：
Hesje, C. E.
中科院分区：
文献类型：
--
作者：
Blondeau, J. M.;Borsos, S.;Hesje, C. E.
溶血性曼氏菌是牛呼吸道疾病（BRD）的最普遍原因，并且这种疾病占发病率的75%，饲养场死亡的50-70%，并且在美国估计每年花费高达10亿美元。抗微生物治疗对于降低发病率、死亡率和减轻这种疾病的经济负担至关重要。由于对增加的抗菌剂耐药性的关注，研究抗菌剂用于选择耐药性的潜力是至关重要的。一种称为突变预防浓度（MPC）的新型体外测量方法定义了阻断高密度（>= 10（7）菌落形成单位/ml）细菌群体（如急性感染中所见）中最不敏感细胞生长所需的抗菌药物浓度。我们比较了5种抗菌药物（头孢噻呋、恩诺沙星、氟苯尼考、替米考星、妥拉霉素）对285 M的最小抑菌浓度（MIC）和MPC值。溶血性临床分离株。每种药剂的MIC 90/MPC 90值分别如下：0.016/2，0.125/1，2/>= 16，8/>= 32，2/8。给药以达到MPC浓度（如可能）可能有助于减少对抗菌药物敏感性降低的细菌亚群的选择。基于MIC 90值的效价排序为头孢噻呋>恩诺沙星>氟苯尼考=图拉霉素>替米考星。基于MPC 90值的效价排序为恩诺沙星>头孢噻呋>图拉霉素>氟苯尼考>=替米考星。(C)2012爱思唯尔有限公司版权所有。
Mannheimia haemolytica is the most prevalent cause of bovine respiratory disease (BRD) and this disease accounts for 75% of morbidity, 50-70% of feedlot deaths and is estimated to cost up to $1 billion dollars annually in the USA. Antimicrobial therapy is essential for reducing morbidity, mortality and impacting on the financial burden of this disease. Due to the concern of increasing antimicrobial resistance, investigation of antibacterial agents for their potential for selecting for resistance is of paramount importance. A novel in vitro measurement called the mutant prevention concentration (MPC) defines the antimicrobial drug concentration necessary to block the growth of the least susceptible cells present in high density (>= 10(7) colony forming units/ml) bacterial populations such as those seen in acute infection. We compared the minimum inhibitory concentration (MIC) and MPC values for 5 antimicrobial agents (ceftiofur, enrofloxacin, florfenicol, tilmicosin, tulathromycin) against 285 M. haemolytica clinical isolates. The MIC90/MPC90 values for each agent respectively were as follows: 0.016/2, 0.125/1, 2/>= 16, 8/>= 32, 2/8. Dosing to achieve MPC concentrations (where possible) may serve to reduce the selection of bacterial subpopulations with reduced antimicrobial susceptibility. The rank order of potency based on MIC90 values was ceftiofur > enrofloxacin > florfenicol = tulathromycin > tilmicosin. The rank order of potency based on MPC90 values was enrofloxacin > ceftiofur > tulathromycin > florfenicol >= tilmicosin. (C) 2012 Elsevier B.V. All rights reserved.